We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
Read MoreHide Full Article
Key Takeaways
PROK surged 515% on positive Phase II data for rilparencel in diabetic chronic kidney disease patients.
Group 1 showed a 78% improvement in kidney decline rate, meeting statistical and clinical benchmarks.
ProKidney will seek FDA confirmation of eGFR slope as a surrogate endpoint in its ongoing Phase III trial.
Shares of ProKidney Corp. (PROK - Free Report) skyrocketed 515% yesterday after the company reported encouraging top-line data from the phase II REGEN-007 study evaluating its lead pipeline drug, rilparencel, in patients with diabetes and chronic kidney disease (CKD).
Results from the study showed that treatment with this experimental therapy exhibited statistically significant and clinically meaningful improvement in the rate of kidney function decline in one of the two dosing groups.
More on ProKidney’s REGEN-007 Study Results
The study randomized patients into two groups — Group 1 and Group 2. While patients in Group 1 received two rilparencel injections three months apart, those in Group 2 initially received a single dose and were given a second one only if they experienced a sustained decline in kidney function.
The prespecified primary endpoint for REGEN-007 was the difference in annual estimated glomerular filtration rate (eGFR) slope, comparing the pre-injection period to the period following the last rilparencel injection. The eGFR slope measures how quickly kidney function declines over time.
Results from the REGEN-007 study showed that the annual decline in eGFR slope improved by 78% in Group 1, which ProKidney claimed was “statistically and clinically meaningful.”
In contrast, Group 2 demonstrated a 50% reduction in annual eGFR decline. Though this result did not reach statistical significance, ProKidney noted that it suggests “evidence of a dose response.”
ProKidney plans to present full results from the REGEN-007 study at the American Society of Nephrology (“ASN”) 2025 Kidney Week as a late-breaking clinical trial.
PROK Share Price Performance
Year to date, the stock has surged 121% compared with the industry’s 4% growth.
Image Source: Zacks Investment Research
What Makes ProKidney’s REGEN-007 Study Results Encouraging?
The FDA had previously communicated to the company that rilparencel would be eligible for approval under the accelerated pathway, provided an accepted surrogate endpoint is used. Since the eGFR slope is a well-established predictor of progression to kidney failure, a significant improvement in this marker could support accelerated approval, pending validation in a late-stage study.
ProKidney plans to meet with the FDA this summer to confirm the use of eGFR slope as the primary surrogate endpoint in the ongoing Phase III PROACT 1 study on rilparencel in subjects with advanced CKD and type 2 diabetes. Additional details from this regulatory dialogue are expected in mid-2025.
The REGEN-007 results have raised the probability of success for rilparencel, given the encouraging efficacy observed in Group 1 as a potential basis for accelerated approval, pending regulatory feedback. This was likely the reason behind the significant jump in PROK stock.
PROK’s Zacks Rank
ProKidney currently carries a Zacks Rank #2 (Buy).
In the past 60 days, Amarin's 2025 loss per share estimates have improved from $3.85 to $2.30. Loss per share estimates for 2026 have narrowed from $3.59 to $1.50 during the same period. AMRN stock has surged 74% year to date.
Amarin’s earnings beat estimates in two of the trailing four quarters, met the mark once and missed in the other, delivering an average surprise of 29.11%.
In the past 60 days, Agenus’ bottom-line estimates for 2025 have significantly improved from a loss of $3.46 per share to earnings of $1.56. During the same timeframe, estimates for 2026 loss per share have narrowed from $3.91 to $1.99. AGEN stock has soared 89% so far this year.
Agenus’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 22.71%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
Key Takeaways
Shares of ProKidney Corp. (PROK - Free Report) skyrocketed 515% yesterday after the company reported encouraging top-line data from the phase II REGEN-007 study evaluating its lead pipeline drug, rilparencel, in patients with diabetes and chronic kidney disease (CKD).
Results from the study showed that treatment with this experimental therapy exhibited statistically significant and clinically meaningful improvement in the rate of kidney function decline in one of the two dosing groups.
More on ProKidney’s REGEN-007 Study Results
The study randomized patients into two groups — Group 1 and Group 2. While patients in Group 1 received two rilparencel injections three months apart, those in Group 2 initially received a single dose and were given a second one only if they experienced a sustained decline in kidney function.
The prespecified primary endpoint for REGEN-007 was the difference in annual estimated glomerular filtration rate (eGFR) slope, comparing the pre-injection period to the period following the last rilparencel injection. The eGFR slope measures how quickly kidney function declines over time.
Results from the REGEN-007 study showed that the annual decline in eGFR slope improved by 78% in Group 1, which ProKidney claimed was “statistically and clinically meaningful.”
In contrast, Group 2 demonstrated a 50% reduction in annual eGFR decline. Though this result did not reach statistical significance, ProKidney noted that it suggests “evidence of a dose response.”
ProKidney plans to present full results from the REGEN-007 study at the American Society of Nephrology (“ASN”) 2025 Kidney Week as a late-breaking clinical trial.
PROK Share Price Performance
Year to date, the stock has surged 121% compared with the industry’s 4% growth.
Image Source: Zacks Investment Research
What Makes ProKidney’s REGEN-007 Study Results Encouraging?
The FDA had previously communicated to the company that rilparencel would be eligible for approval under the accelerated pathway, provided an accepted surrogate endpoint is used. Since the eGFR slope is a well-established predictor of progression to kidney failure, a significant improvement in this marker could support accelerated approval, pending validation in a late-stage study.
ProKidney plans to meet with the FDA this summer to confirm the use of eGFR slope as the primary surrogate endpoint in the ongoing Phase III PROACT 1 study on rilparencel in subjects with advanced CKD and type 2 diabetes. Additional details from this regulatory dialogue are expected in mid-2025.
The REGEN-007 results have raised the probability of success for rilparencel, given the encouraging efficacy observed in Group 1 as a potential basis for accelerated approval, pending regulatory feedback. This was likely the reason behind the significant jump in PROK stock.
PROK’s Zacks Rank
ProKidney currently carries a Zacks Rank #2 (Buy).
ProKidney Corp. Price
ProKidney Corp. price | ProKidney Corp. Quote
Other Key Picks Among Biotech Stocks
Some other top-ranked stocks from the sector are Amarin Corporation (AMRN - Free Report) and Agenus (AGEN - Free Report) . While AMRN sports a Zacks Rank #1 (Strong Buy) at present, Agenus carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, Amarin's 2025 loss per share estimates have improved from $3.85 to $2.30. Loss per share estimates for 2026 have narrowed from $3.59 to $1.50 during the same period. AMRN stock has surged 74% year to date.
Amarin’s earnings beat estimates in two of the trailing four quarters, met the mark once and missed in the other, delivering an average surprise of 29.11%.
In the past 60 days, Agenus’ bottom-line estimates for 2025 have significantly improved from a loss of $3.46 per share to earnings of $1.56. During the same timeframe, estimates for 2026 loss per share have narrowed from $3.91 to $1.99. AGEN stock has soared 89% so far this year.
Agenus’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 22.71%.